Abstract: The goal of the pharmacological therapy in secondary hyperparathyroidism (SHPT) is to reduce serum levels of parathyroid hormone and phosphorus, to correct those of calcium and vitamin D, to arrest or reverse the parathyroid hyperplasia. However, when nodular hyperplasia or an autonomous adenoma develops, surgery may be indicated. We reviewed the literature with the aim of defining if the echographic criteria predictive of unresponsiveness of SHPT to calcitriol therapy are valid also in the cinacalcet era and if drug therapy may reverse nodular hyperplasia of parathyroid gland (PTG). The responsiveness to therapy and regression of the nodular hyperplasia of PTG remains an open question in the calcimimetic era as well as the cutoff between medical and surgical therapy. Prospective studies are needed in order to clarify if an earlier use of cinacalcet in moderate SHPT might arrest the progression of parathyroid growth and stabilize SHPT.
Secondary hyperparathyroidism (SHPT) is a severe complication of patients on chronic hemodialysis responsible for substantial morbidity and mortality related to osteodystrophy and vascular and soft-tissue calcification (1) (2) (3) (4) (5) . Although the pathogenesis of SHPT is not completely known, it appears evident that the hypocalcemia, hyerphosphatemia and low calcitriol concentrations determine, along with time, the hyperplasia of parathyroid glands (PTG) , that is initially polyclonal diffuse (DH) and reversible and successively monoclonal nodular (NH) and irreversible (6) . The nodular or adenomatous PTG begins to function autonomously, continuing to secrete PTH even if hypocalcemia is corrected. This condition is referred to as 'refractory' SHPT and is also sometimes called 'tertiary' hyperparathyroidism (7, 8) . In effect, also after successful kidney transplantation, while the diffuse hyperplasia (DH) may have a tendency to regress, nodular hyperplasia (NH) is unlikely to do so (9) ( Table 1) .
Since several years, it was shown that the calcium non-suppressible PTH secretion correlates with the degree of PTG enlargement and severity of SHPT (10) . Effectively, the PTG hyperplasia is associated with a progressive downregulation of calcium sensing (CaSR) and vitamin D (VDR) receptors (11) (12) (13) (14) . The receptors downregulation may influence the proliferation of hyperplasia and it may help explain the unresponsiveness to drug therapy (15, 16) . Thus, when NH develops, drug therapy is more likely to fail and at this point of SHPT evolution, surgery may be indicated (17) . Since the early 1980s, Clark et al. (18) argued that "the size of the PTG correlated positively with the severity of the SHPT. Thus, the preoperative identification of enlarged PTG by ultrasonography detects those patients who are thus unlikely to respond to further medical therapy". Indeed, a recent study has shown that the larger the PTG is, the higher the production of PTH is (19) . 
C Vulpio and M Bossola
Despite these observations, dating back over 30 years ago, ultrasosonography of PTG has been used to localize PTG before parathyroidectomy and, rarely, in routine clinical practice to determine the indication for surgery according to PTG size and the ultrasonography of PTG is rarely used in everyday clinical practice to determine the indication for surgery. In fact, not all recent international guidelines on the treatment of SHPT recommend the evaluation of the PTG size in the surgical decision-making. Actually, the Japanese Society for Dialysis Therapy (JSDT) (20) has affirmed that the assessment of any PTG masses by echography is an important factor predictive of the response to medical treatment and useful to make decisions regarding surgical treatment. Conversely, the NFK-KDOQI (21) and the K-DIGO guidelines (22) do not indicate the volume or diameter of the PTG above which surgery is indicated. Although the ultrasonography of PTG is today able to define accurately the gland size and the vascular and structural shapes suggestive of type of hyperplasia, it is rarely used to determine the cut off between medical and surgical therapy (15, (23) (24) (25) (26) (27) (28) . Therefore, the definition of the 'point of no return' for drug therapy remains an unresolved issue as well as does the indication for parathyroidectomy. Really, this debate has become more relevant after the introduction of cinacalcet in clinical practice. In particular, it still remains controversial if the ultrasonography could be useful to predict the response to pharmacological therapy also in the calcimimetic era.
The present review aims to evaluate if the echographic criteria defining SHPT refractory to therapy with vitamin D alone are valid also in the cinacalcet era and if the drug therapy (i.e. calcitriol alone or cinacalcet and calcitriol or vitamin D analogs) may reverse PTG hyperplasia.
CURRENT PROBLEM OF MANAGEMENT OF SHPT: THE STATE OF THE ART
Although the severity of SHPT of patients on hemodialysis is defined by the metabolic parameters (PTH, calcium, phosphorus, alkaline phosphatases), the normal upper limits of PTH have not yet been established (the JSDT guidelines consider acceptable PTH <240 pg/mL, whereas NFK-KDOQI and K-DIGO guidelines suggest values <300 pg/mL and <600 pg/mL, respectively). Consequently, because the targets of drug therapy and the criteria to classify the patients into responders and nonresponders are still ambiguous, it is difficult to compare the studies reported. Some studies show the final percentage reduction of PTH from baseline, others the percentage of achievement of the recommended targets of calcium, phosphorus and PTH, individually considered or all three together. Moreover, in several studies, patients were considered according to the PTH classes [mild (<500 pg/mL), moderate (500-800 pg/mL), and severe (>800 pg/mL)] (29) .
Despite the aforesaid limits, before the availability of cinacalcet, the medical treatment of SHPT was overall far from optimal, with approximately 60% of patients not achieving adequate control of PTH, calcium and phosphorus levels. Usually, nearly all the patients with PTH >1000 pg/mL did not reach the recommended targets (30, 31) . Conversely, the overall percentage of the responsiveness to treatment increased with the introduction of the cinacalcet (40-80 %) also in patients with very high basal PTH concentrations (32, 33) . Moreover, the EVOLVE study, although it demonstrated controversial results on the basis of primary unadjusted intention to treat (ITT)-based analysis or prespecified secondary analysis in terms of cardiovascular outcomes, has shown that cinacalcet significantly prevented the need for parathyroidectomy and the occurrence of severe unremitting SHPT. In addition, it should be considered that poor adherence may have accounted also for insufficient PTH reduction in some patients. (34) (35) (36) (37) (38) (39) (40) (41) (42) . However, although the use of cinacalcet has increased in the last decade, its effectiveness remains uncertain as well as how it fits in the management of SHPT of dialysis patients (43, 44) . Moreover, it is still debated when and how long will cinacalcet be necessary, and at what cost. In effect, it was recently reported (45) that a large proportion of patients succumb to adverse events limiting its use, and even those who remain on the medication for an extended period of time experience side-effects and fail to demonstrate significant decreases in PTH levels. Nevertheless, Konstantinidis et al. (46) showed that a significant proportion of ESRD patients who met indications for parathyroidectomy did not receive it. In addition, the study of van der Plas et al. (47) showed that the introduction of cinacalcet is associated with a significant 2-year delay of surgery despite the continuously elevated preoperative PTH levels. Therefore, although parathyroidectomy is a safe and effective procedure even in a fragile population, it is still underutilized. Unfortunately, up to now, there are no specified criteria, either biochemical or otherwise, that may prompt the parathyroidectomy. The indications for parathyroidectomy (PTx), as suggested by the different guidelines, are
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controversial. Actually, the JSDT recommends PTx for severe SHPT (PTH levels > 500 pg/mL) refractory to medical treatment. The rating of such a guideline is Level 1 and the quality of evidence is moderate (B). Conversely, NKF-KDOQI suggests that "PTx should be recommended in patients with severe SHPT (persistent serum levels of PTH >800 pg/mL), associated with hypercalcemia and/or hyperphosphatemia that are refractory to medical therapy. However, this statement is considered "opinion". Finally, the KDIGO Guidelines recommend PTx in patients with CKD stages 3-5D with severe SHPT who fail to respond to medical/pharmacological therapy. However, these guidelines do not indicate the levels of PTH and the level of evidence (2) and the quality (moderate) are lower than those of the JSDT. Indeed, guidance for the indications for parathyroidectomy are significantly hampered by a lack of randomized, controlled trials comparing the longterm effects of medical versus surgical therapy of the advanced SHPT. Nevertheless, several observational studies showed that parathyroidectomy improves survival and cardiovascular outcomes (48) (49) (50) (51) (52) (53) . In fact, these studies demonstrated improvement of cardiac function (54), left ventricular hypertrophy (55) , attenuation of progression of vascular calcification (56) after parathyroidectomy. Furthermore, other possible mechanisms for improved survival after parathyroidectomy could be the reduction of fibroblast growth factor 23 and the fracture risk (57, 58) , improvement of anemia (59), hypertension (60), cardiac autonomic nervous system (61), immune system (62), and muscle strength (63) .
Finally, because limitations of resources in public health systems demand detailed analyses of accruing costs, several studies compared the costs of surgical and new drug therapy (cinacalcet phosphate binders, paricalcitol) in patients with SHPT (64) (65) (66) (67) (68) (69) . The majority of studies showed that the indication of these new drugs should be restricted to patients as an interim solution ahead of surgery or in patients considered unfit for surgery. Therefore, to reduce the health costs, it could be crucial today to integrate the biochemical criteria of the severity of SHPT with morphological parameters of the degree of PTG hyperplasia in order to identify more precociously the patients for which it is appropriate to desist from prolonged and expensive medical therapy (70) .
In other words, regardless of the PTH values, why do some patients respond to therapy and others do not? Perhaps, these patients suffer from refractory SHPT due to nodular or adenomatous PTG hyperplasia. Nevertheless, there are a few studies that have investigated the responsiveness of SHPT to drug therapy related to the degree of parathyroid hyperplasia evaluated by ultrasonography. In addition, a few studies have assessed a possible regression of PTG hyperplasia. Hereinafter, we will examine the studies that have assessed the SHPT response to therapy with vitamin D or analogues and cinacalcet.
Ultrasound Evidence of Responsiveness and Regression of Parathyroid Gland Hyperplasia after Calcitriol or Analogues Therapy
Fukagawa et al. (71, 72) reported that patients with at least one PTG > 0.5 cm 3 volume (10 mm in diameter) were usually refractory to calcitriol therapy. In effect, Indridason et al. (10) , showed a significant linear correlation between the PTG size and ending PTH suppression and slope of the calcium-PTH curve. These results were confirmed by Malberti et al. (73) who studied 35 patients before and after 12 months of intravenous calcitriol therapy and showed that the only significant predictors of a favorable response to calcitriol therapy at the logistic regression analysis were the PTG size and the set point of calcium. In effect, the total volume of PTG (i.e. the sum of the volumes of the glands detected by ultrasonography) of patients responsive and noresponsive to therapy were respectively 400 ± 300 mm 3 and 2400 ± 2100 mm 3 (81), in a prospective crossover study in which 11 patients were randomized to receive intravenous followed by oral calcitriol for 4 months each, or oral followed by intravenous calcitriol, showed that no size reduction of PTG was demonstrable after treatment. Quarles et al. (82) , in a prospective trial confirmed that long-term intensive calcitriol therapy failed to decrease PTG size independently of administration route.
More recently, Taniguchi et al. (83) , in 58 patients on hemodialysis, conducted a prospective randomized study to investigate the inhibitory effects of oral or intravenous calcitriol therapy in the initial phase of SHPT, in which PTG enlargement begins, on PTG enlargement. The authors measured by ultrasonography the total volume of PTG and the volume of the largest PTG before and 12 months after the start of oral or intravenous calcitriol administration. These volumes, similar in both groups before the therapy, 12 months after therapy were significantly increased in the oral group, but unchanged in the intravenous group. The authors suggested that a precocious intravenous calcitriol therapy in the early stage of SHPT, corresponding to the phase of diffuse hyperplasia, may prevent the deterioration to nodular hyperplasia, avoiding the parathyroidectomy.
Finally, all of these studies show that calcitriol or its analogues are more effective in the early and less severe stages of SHPT and may arrest the development of the PTG hyperplasia; but they are ineffective in advanced SHPT supported by nodular hyperplasia which remains an irreversible phenomenon to vitamin D therapy.
Ultrasound Evidence of Responsiveness and Regression of PTG Hyperplasia After Cinacalcet Use
Cinacalcet modulates the sensitivity of CaSR of parathyroid chief cells, suppresses the release of PTH and plays a key role in the excessive parathyroid cell proliferation. However, in this regard, the in vitro and in vivo experimental studies have led to conflicting results. Mizobuchi et al. (84) have demonstrated that the calcimimetic in vitro determines apoptosis of parathyroid cells, whereas Colloton et al. (85) , showed that the administration of cinacalcet HCl in rats in vivo significantly reduced the number and volume of proliferating cells, but it does not increase apoptosis. Although other (86-88) authors have also failed to detect apoptosis in parathyroid cells in vivo, the initial observations led some authors to hypothesize that cinacalcet may generate a pharmacological parathyroidectomy.
Indeed, conflicting findings have been reported also in humans about the responsiveness to cinacalcet therapy and the effectiveness to determine the regression of PTG hyperplasia (Table 2 ). Tanaka et al. (89) studied 12 patients with large PTG (>500 mm 3 ) and considered to have nodular hyperplasia, and eight patients with small PTG considered without nodular hyperplasia. This study concluded that cinacalcet lacks long-term efficacy in nodular hyperplasia, especially for controlling serum calcium and phosphorus levels. Meola et al. (90) treated with cinacalcet nine patients in whom ultrasonography identified overall 28 hyperplastic PTG. Although all patients were responsive to therapy, the overall volume of the PTG did not change significantly during the course of the study. However, the PTG with a baseline volume-500 mm 3 changed significantly, while the PTG with a baseline volume > 500 mm 3 did not change. However, 2 weeks after cinacalcet interruption, a rebound of PTH levels occurred in all patients, even in those with major involutive phenomena of PTG and lower values of PTH at the end of the follow-up. On the contrary, the study of Komaba et al. (91) showed that cinacalcet therapy resulted in a significant reduction in PTG volume regardless of pretreatment size. The author evaluated 81 patients who underwent cinacalcet therapy for 52 weeks and 56 patients who had PTG smaller than 500 mm 3 (group S) and 25 who had at least one enlarged PTG larger than 500 mm 3 (group L). During the efficacy-assessment phase, 46 % of patients in group S and 32 % of those in group L reached the primary end point of a mean intact PTH level < 180 pg/mL. The total volumes of each patients' gland were significantly reduced after the cinacalcet treatment. Significant volume reductions were observed both in PTG with baseline volume > 500 mm 3 and in PTG with baseline volume < 500 mm 3 . However, the proportion of subjects who achieved simultaneous control of PTH, calcium, and phosphorus was significantly higher in group S than in group L.
The study of Kakuta et al. (92) reached opposite conclusions. The authors evaluated 61 patients receiving cinacalcet for 6 months and considered to be "effective cases" those who achieved the K/DOQI guidelines targets (PTH <300 pg/mL, calcium <10 mg/dL and phosphorus < 6 mg/dL). Multivariate analysis demonstrated that the number of enlarged PTG had the strongest influence, with a tendency for treatment to be less effective in patients with a greater number of enlarged PTG. Moreover, there was not a significant difference in the individual and total volume of PTG after 6 months treatment, since some PTG enlarged while others were reduced. Ichii et al. (93) examined by ultrasonography 58 patients after 6 months of cinacalcet treatment and showed that the total volumes of PTG were significantly decreased. However, the total volume of PTG was decreased in 42 and increased in 16 out of 58 patients. Furthermore, it is of note that iPTH levels were significantly decreased both in patients with decreased and those with increased total volume of PTG. Hirai et al. (94, 95) examined the effect of 12 months of cinacalcet in 31 patients divided into two groups on the basis of PTG volume: group S (N = 16, volume < 500 mm 3 ) considered without nodular hyperplasia, and group L (N = 15, volume-500 mm 3 ) with nodular hyperplasia. After 6 months the clinical effect of therapy was similar in the two groups. However, while in group S the iPTH continued to decrease throughout the 12-month study period, in group L the iPTH significantly increased gradually at 12 months. Finally, the PTG size (i.e. the single and total volume of PTG) did not change significantly after 12 months cinacalcet therapy. In conclusion, the authors suggest that the existence of nodular hyperplasia is associated with resistance to long-term cinacalcet therapy and that detection of nodular hyperplasia may be useful for predicting the long-term response of SHPT to cinacalcet. Similar results were reported by Vulpio et al. (96) who evaluated the effect of 12 months of cinacalcet in 11 patients with overall 22 enlarged PTG detected both at ultrasonography and 99Tc-Sestamibi scintigraphy. After 12 months, the PTH, diameter and volume of PTG remained substantially unchanged in most of the patients. Vulpio et al. (97) , in another retrospective study, compared the echographic parameters of PTG of patient responders (R) and non-responders (NR) to two different therapies (vitamin D alone: group A, N = 39; vitamin D plus cinacalcet: group B, N = 30). The baseline ultrasound characteristics of PTG (number, maximum diameter and structural and vascular patterns) of R patients were lower than NR ones regardless of the different therapy. The authors concluded that the long-term drug therapy (based on vitamin D or vitamin D plus cinacalcet) may be helpful in patients with PTG < 10 mm and useless in patients with PTG > 10 mm. Yamamoto et al. (98) evaluated by ultrasonography 57 patients before and after 28-weeks of cinacalcet therapy. On the basis of final PTH levels, the patients were divided into Group A (PTH ≤180 pg/mL) and Group B (PTH >180 pg/mL). The number of enlarged PTG (volume ≥ 500 mm 3 or diameter ≥ 10 mm), which presumably had nodular hyperplastic lesions, the largest and the total volume of detectable PTG were significantly greater in Group B compared with Group A. In multivariate logistic regression analysis, patients with two or more enlarged PTGs had a significant risk of poor response to cinacalcet treatment. Yamada et al. (99) in a multicentric prospective observational study enrolled 60 patients who could not achieve the JSDT targets (<180 pg/ mL) with vitamin D therapy and who had at least one PTG detected by ultrasonography. Two years of cinacalcet treatment decreased serum intact PTH levels, and 60% of patients achieved PTH target irrespective of baseline values and PTG volume. Overall, both total and largest PTG volumes significantly decreased during the first 6 months, and continued decreasing gradually thereafter. However, the authors showed that the presence of nodular hyperplasia (at least one PTG > 500 mm 3 ) was significantly associated with "treatment failure" (i.e. PTH level > 180 pg/mL after 2 years of cinacalcet treatment). Moreover, multivariable analysis showed that patients with nodular PTG at baseline and patients with higher serum calcium and PTH levels at 1 year were likely to exceed the target range of PTH at 2 years. PTG ≥ 11.2 mm on CT significantly influenced the response to cinacalcet treatment. The authors concluded that the existence of enlarged PTGs equal to or larger than the cutoff value was the most significant factor of unresponsiveness to cinacalcet. Finally, all of these studies show that cinacalcet also is more effective in the early and less severe stages of SHPT but it may be ineffective in advanced SHPT with nodular hyperplasia. Unfortunately, so far there is no evidence of regression of nodular hyperplasia after cinacalcet therapy.
WHAT HISTOLOGICAL STUDIES OF THE HUMAN PTG DO SUGGEST?
Recent studies (102-106) compared histological and immunohistochemical features of PTG of patients who received vitamin D and cinacalcet with respect to those treated with vitamin D alone before the surgery, and failed to find significant differences between two groups of patients. However, it is useful to underline that the primary limitation of such studies is that they included only patients with severe SHPT who underwent parathyroidectomy. Thus, no studies could have evaluated the changes in parathyroid histology after cinacalcet prescription among vitamin D and/or cinacalcet responders.
Sumida et al. (102) reported that, in patients who received vitamin D and cinacalcet with respect to those treated with vitamin D alone, the number, diameters and weight of PTG were similar. In a successive study (103) , the same authors showed that, compared with normal glands, the expression of CaSR was significantly decreased in both the cinacalcet and conventional groups. In particular, the expression of CaSR was significantly decreased in the larger glands (>500 mg) compared with that in the smaller glands (<500 mg) and it was markedly decreased in areas of nodular hyperplasia compared with diffuse hyperplasia. Although the expression of CaSR was significantly increased in the cinacalcet group compared with the conventional one, the insufficient expression of CaSR in larger PTG with nodular hyperplasia underlies the unresponsiveness to cinacalcet therapy. Vulpio et al. (104) confirmed the macroscopic and microscopic results of Sumida. The author showed that the TUNEL, Ki-67 labeling index and VEGF scores were significantly higher in nodular than in diffuse hyperplastic areas of PTG whereas the CaSR scores were lower in the same areas, but the immunohistochemical patterns of PTG of patients who received or did not receive cinacalcet before surgery were not significantly different. Lee et al. (105) recently confirmed the downregulation of CaSR in nodular hyperplasia compared with normal PTG. In addition, the author reported that the rate of cell proliferation is greater than the rate of apoptosis in nodular hyperplasia, therefore he suggests that a calcimimetic compound should be used carefully in patients with nodular hyperplasia. Finally, Tatsumi et al. (106) suggest that cinacalcet induces apoptosis of human parathyroid cells, but this effect may be overcome by more aggressive cellular proliferation.
CONCLUSION
The responsiveness of secondary hyperparathyroidism to medical therapy has long been the clinical query for the last few decades. Before the cinacalcet era, the volume or size of PTG (indicative of nodular hyperplasia) was undoubtedly an important factor in predicting the future responsiveness to Vitamin D or analogue therapy. Instead, in regard to therapy with cinacalcet, this evidence appears to be confirmed by some studies and contradicted by others. In effect, these observational studies, which have examined the efficacy of cinacalcet in relation to the degree of hyperplasia, show serious limitations (i.e. few patients, different durations of treatment, classifications of the degree of PTG hyperplasia and criteria defining therapeutic targets) which can explain the discordant results. Therefore, the responsiveness to therapy and regression of the nodular hyperplasia of PTG remains an open question in the calcimimetic era and so the 'point of no return' of drug therapy and the cutoff between medical and surgical therapy remain controversial. Additional studies on cinacalcet therapy are needed in order to clarify if an earlier utilization of cinacalcet in moderate SHPT (PTH 300-800 pg/mL) could be able to arrest the progression of parathyroid growth and to stabilize SHPT. However, clinicians should seriously consider the benefits and harms of the prolonged use of cinacalcet versus parathyroidectomy to control unremitting hyperparathyroidism.
